ZUNVEYL Patent Gets FDA's Official Review Timer
Published Date: 8/26/2025
Notice
Summary
The FDA has officially set the review period for ZUNVEYL, a human drug product, so its patent can be extended. This means the company behind ZUNVEYL gets more time to protect their invention and keep competitors at bay. If you’re in the drug business or follow patents, this update signals important timing for patent rights and market exclusivity.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in